



# PANEL DISCUSSION: BIOMARKERS AND OUTCOME MEASURES IN PD CLINICAL TRIALS

---

**ISCTM Symposium**  
**February 22, 2018**

# BIOMARKERS AND OUTCOME MEASURES IN PD CLINICAL TRIALS

## **Diane Stephenson, PhD**

Executive Director, Critical Path for Parkinson's  
Acting Director, Huntington's Disease Regulatory  
Science Consortium

## **Luca Pani, MD**

Professor of Clinical Psychiatry  
University of Miami

## **Christopher Leptak, MD, PhD**

OND Biomarker Qualification Lead  
CDER/FDA

## **David Stamler, MD**

Chief Medical Officer  
Prana Biosciences



# QUESTIONS FOR DISCUSSION

- » How would you utilize and integrate existing biomarkers into Parkinson's clinical trials?
- » What are the challenges in testing interventions in genetically defined populations of Parkinson's patients?
- » What are the scientific and regulatory considerations to testing an intervention in a 'prodromal' PD population?

